Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article.
J Immunoassay Immunochem
; 41(6): 960-975, 2020 Nov 01.
Article
in English
| MEDLINE | ID: covidwho-1104705
ABSTRACT
In December 2019, an outbreak of pandemic severe respiratory distress syndrome coronavirus disease 2019 (COVID-19) initially occurred in China, has spread the world resulted in serious threats to human public health. Uncommon neurological manifestations with pathophysiological symptoms were observed in infected patients including headache, seizures, and neuroimmunological disorders. Regardless of whether these neurological symptoms are direct or indirect casual infection relationship, this novel viral infection has a relevant impact on the neuroimmune system that requires a neurologist's careful assessment. Recently, the use of immunotherapy has been emerged in fighting against COVID-19 infection despite the uncertain efficiency in managing COVID-19 related disorders or even its proven failure by increasing its severity. Herein, the author is addressing the first approaches in using immunotherapies in controlling COVID-19 viral impact on the brain by highlighting their role in decreasing or increasing infection risks among subjects. This point of view review article supports the use of immunotherapies in managing COVID-19 neurological disorders but in optimal timing and duration to ensure the maximum therapeutic outcome by reducing morbidity and mortality rate. Based on recently published data, the current review article highlights the beneficial effects and drawbacks of using immunotherapies to combat COVID-19 and its neurological symptoms.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cytokine Release Syndrome
/
COVID-19
/
Immunotherapy
/
Nervous System Diseases
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
J Immunoassay Immunochem
Journal subject:
Allergy and Immunology
Year:
2020
Document Type:
Article
Affiliation country:
15321819.2020.1865400
Similar
MEDLINE
...
LILACS
LIS